Locations
Brisbane, QLD, Australia · Sydney, NSW, Australia · Sydney NSW, Australia
Size
51-200 employees
founded in
2011
Vaxxas is a biotechnology company commercializing a novel needle-free vaccination technology called HD-MAP, which utilizes a patch with thousands of microprojections to deliver vaccines efficiently to immune cells in the skin. This innovative approach enhances the performance of existing and next-generation vaccines, shifting the value paradigm of vaccination. The HD-MAP platform has been productized for commercial use, validated in human clinical studies, and designed for large-scale manufacturing. Vaxxas has made significant strides in expanding its global IP portfolio and has initiated various clinical trials, positioning itself as a leader in the needle-free vaccination market.
Something looks off?